



Palliative Low Grade Lymphoma & Hairy Cell Leukemia Regimens

The following table lists the evidence-informed regimens (both IV and non-IV) for low grade lymphoma and Hairy Cell leukemia used in the palliative setting. It is expected that the prescribing oncologist will select the regimen from the list of evidence-informed regimens that is most appropriate for their patient taking account of a variety of disease-specific and patient-related factors.

Regimens highlighted in red contain an expensive drug that is not currently publicly funded for the regimen and treatment intent.

| Low Grade Lymphoma | |
|--------------------|---|
| Regimen Code | Regimen Abstract |
| BAC+RITU | RiTUXimab 375 mg/m ² IV Day 1 Bendamustine 70 mg/m ² IV Days 2 and 3 Cytarabine 500-800 mg/m ² IV Days 2 to 4 Q28 days For use in Mantle-Cell Lymphoma |
| BEND+RITU | Bendamustine 90 mg/m ² IV days 1-2; riTUXimab 375 mg/m ² IV day 1. Q28 days |
| CHLO | <i>Dose and frequency may vary, one option is:</i> Chlorambucil 6 mg/m ² PO days 1-14. Q28 days Can be given with or without prednisone |
| CHLO+RITU | Chlorambucil 6 mg/m ² PO days 1-14; riTUXimab 375 mg/m ² IV day 1. Q28 days |
| CHOP | Cyclophosphamide 750 mg/m ² IV day 1; DOXOrubicin 50 mg/m ² IV day 1; vinCRISStine 1.4 mg/m ² (max 2 mg) IV day 1; Prednisone 100 mg PO days 1-5. Q21 days |

Low Grade Lymphoma

| Regimen Code | Regimen Abstract |
|---------------|---|
| CHOP+R | <p>Cyclophosphamide 750 mg/m² IV day 1; DOXOrubicin 50 mg/m² IV day 1; vinCRISStine 1.4 mg/m² (max 2 mg) IV day 1; Prednisone 100 mg PO days 1-5; riTUXimab 375 mg/m² IV day 1. Q21 days</p> |
| CHOP+R-DHAP+R | <p>CHOP+R (x 3 cycles): Cyclophosphamide 750 mg/m² IV day 1; DOXOrubicin 50 mg/m² IV day 1; vinCRISStine 1.4 mg/m² (max 2 mg) IV day 1; Prednisone 100 mg PO days 1-5; riTUXimab 375 mg/m² IV day 1. Q21 days</p> <p>DHAP+R (x 3 cycles): Adapted for outpatient administration CISplatin 100 mg/m² CIV over 8 hours day 1; Cytarabine 2000 mg/m² IV over 2 hours Q12 hours x 2 doses, day 2; Dexamethasone 40 mg PO days 1-4; riTUXimab 375 mg/m² IV day 1. Q21-28 days</p> |
| CLAD | <p>Cladribine 0.12-0.14 mg/kg IV days 1-5</p> <p><i>Alternative schedules:</i> Cladribine 0.09 - 0.1 mg/kg CIV for 5-7 days Cladribine 0.14mg/kg IV weekly for 6 weeks</p> |
| CLAD+RITU | <p>Cladribine 0.12-0.14 mg/kg IV days 1-5; riTUXimab 375 mg/m² IV weekly for 4 - 8 weeks. Rituximab can be given concurrently or following Cladribine</p> <p><i>Alternative schedule:</i> Cladribine 0.09 - 0.1 mg/kg CIV for 5-7 days riTUXimab 375 mg/m² IV weekly for 4 - 8 weeks. Rituximab can be given concurrently or following Cladribine</p> |
| CNOP | <p>Cyclophosphamide 750 mg/m² IV day 1; vinCRISStine 1.4 mg/m² (max 2 mg) IV day 1; MitoXANTRONE 10 mg/m² IV day 1; Prednisone 50 mg/m² PO days 1-5. Q21 days</p> |
| CVP | <p>Cyclophosphamide 750 mg/m² IV day 1; vinCRISStine 1.4 mg/m² (max 2 mg) IV day 1; Prednisone 100 mg PO days 1-4. Q21 days</p> |

Low Grade Lymphoma

| Regimen Code | Regimen Abstract |
|---------------|---|
| CVP(PO) | Cyclophosphamide 400 mg/m ² PO days 1-5; vinCRISStine 1.4 mg/m ² (max 2 mg) IV day 1; prednisone 100 mg PO days 1-5. Q21 days |
| CVP+R | Cyclophosphamide 750 mg/m ² IV day 1; vinCRISStine 1.4 mg/m ² (max 2 mg) IV day 1; Prednisone 100 mg PO days 1-5; riTUXimab 375 mg/m ² IV day 1. Q21 days |
| CVP(PO)+R | Cyclophosphamide 400 mg/m ² PO days 1-5; vinCRISStine 1.4 mg/m ² (max 2 mg) IV day 1; Prednisone 100 mg PO days 1-5; riTUXimab 375 mg/m ² IV day 1. Q21 days |
| CYCL(PO) | <i>Dose and frequency may vary;</i> Cyclophosphamide 500 mg PO Weekly Or Cyclophosphamide 50 mg PO daily Can be given with or without Prednisone |
| CYCL+RITU | Cyclophosphamide 750 mg/m ² IV day 1; riTUXimab 375 mg/m ² IV day 1. Q21 days |
| CYCLDEXA+RITU | Cyclophosphamide 100 mg/m ² PO BID days 1-5; Dexamethasone 20 mg IV day 1; riTUXimab 375 mg/m ² IV day 1. Q21 days |
| FC | Fludarabine 25 mg/m ² IV days 1-3; Cyclophosphamide 250 mg/m ² IV days 1-3. Q28 days |
| FC+R | Fludarabine 25 mg/m ² IV days 1-3; Cyclophosphamide 250 mg/m ² IV days 1-3; riTUXimab 375 mg/m ² IV day 1. Q28 days |
| FCM | Fludarabine 25 mg/m ² IV days 1-3; Cyclophosphamide 200-250 mg/m ² IV days 1-3; mitoXANTRONE 6 mg/m ² IV day 1. Q28 days |

Low Grade Lymphoma

| Regimen Code | Regimen Abstract |
|----------------|--|
| FCM+R | Fludarabine 25 mg/m ² IV days 1-3; Cyclophosphamide 200-250 mg/m ² IV days 1-3; mitoXANTRONE 6 mg/m ² IV day 1; riTUXimab 375 mg/m ² IV day 1. Q28 days |
| FLUD | Fludarabine 25 mg/m ² IV days 1-5. Q28 days |
| FLUD+R | Fludarabine 25 mg/m ² IV days 1-5; riTUXimab 375 mg/m ² IV day 1. Q28 days |
| GDP | Gemcitabine 1000 mg/m ² IV days 1 and 8; Dexamethasone 40 mg PO days 1-4; CISplatin 75 mg/m ² IV day 1. Q21 days <i>Note: For use in selected patients with R/R indolent NHL</i> |
| GEMC | Gemcitabine 1000 - 1,200 mg/m ² IV days 1, 8, 15. Q28 days <i>Alternative Schedule:</i> Gemcitabine 1000mg/m ² IV days 1, 8. Q21 days |
| HYPERCVAD+RITU | <i>Adapted for outpatient administration</i> Course A: Cyclophosphamide 600 mg/m ² IV days 1-3 (max dose 1320 mg); DOXOrubicin 50 mg/m ² IV day 4*; vinCRISTine 1.4 mg/m ² (max dose 2 mg) IV days 4* and 11; Dexamethasone 40 mg PO days 1, 2, 3, 4, 11, 12, 13, 14; riTUXimab 375 mg/m ² IV day 1. Q21-28 days *some centres may administer on day 3 Course B: Inpatient |
| MTRX(IT) | Methotrexate 12 mg IT <i>Schedule and frequency depends on treatment intent and disease status (i.e. prophylactic or established CNS involvement)</i> |
| MTRX(PO) | Methotrexate 5.0 mg to 7.5 mg PO once weekly, with escalation up to 10 mg/m ² /wk. |
| RITU | riTUXimab 375 mg/m ² IV days 1, 8, 15, 22. |

Low Grade Lymphoma

| Regimen Code | Regimen Abstract |
|--------------|---|
| RITU(MNT) | riTUXimab 375 mg/m ² IV day 1. Q12 weeks |
| BEND | Bendamustine 120 mg/m² IV days 1-2 – not currently publicly funded for this regimen and intent. Q21 days |
| BEND+OBIN | Bendamustine 90 mg/m² IV days 1-2 – not currently publicly funded for this regimen and intent; oBINutuzumab 1000 mg IV days 1, 8, 15 (cycle 1 only) THEN oBINutuzumab 1000 mg IV day 1 of cycles 2 to 6 – not currently publicly funded for this regimen and intent; Q28 days <i>Note: **For use in patients with rituximab-refractory disease. See GADOLIN paper for details. For maintenance use, report as Regimen Code: OBIN(MNT) after BEND+OBIN induction**</i> |
| BORT | Bortezomib 1.3 mg/m² IV/SC days 1, 4, 8, 11 – Not currently publicly funded for this regimen and intent Q21 days For use in Mantle-Cell Lymphoma |
| BORTGEMC | Bortezomib 1 mg/m² IV/SC days 1, 4, 8, 11 – not currently publicly funded for this regimen and intent; Gemcitabine 1000 mg/m ² IV days 1, 8. Q21 days |
| FC(PO) | Fludarabine 25 mg/m² PO daily days 1-5 – Not currently publicly funded for this regimen and intent Cyclophosphamide 150 mg/m ² PO daily days 1 -5. Q28 days |
| FC(PO)+R | Fludarabine 25 mg/m² PO days 1-5 – Not currently publicly funded for this regimen and intent Cyclophosphamide 150 mg/m ² PO days 1-5; riTUXimab 375 mg/m ² IV day 1. Q28 days |
| FCM(PO) | Fludarabine 25 mg/m² PO days 1-5 - Not currently publicly funded for this regimen and intent; Cyclophosphamide 150 mg/m ² PO days 1-5; MitoXANTRONE 6 mg/m ² IV day 1; Q28 days |
| FCM(PO)+R | Fludarabine 25 mg/m² PO days 1-5 - Not currently publicly funded for this regimen and intent; Cyclophosphamide 150 mg/m ² PO days 1-5; MitoXANTRONE 6 mg/m ² IV day 1; RiTUXimab 375 mg/m ² IV day 1; Q28 days |

Low Grade Lymphoma

| Regimen Code | Regimen Abstract |
|--------------|--|
| FLUD(PO) | Fludarabine 40 mg/m ² /day PO days 1-5 – Not currently publicly funded for this regimen and intent Q28 days |
| FLUD(PO)+R | Fludarabine 40 mg/m ² /day PO days 1-5 – Not currently publicly funded for this regimen and intent riTUXimab 375 mg/m ² IV day 1. Q28 days |
| IDEL | Idelalisib 150 mg PO BID – until progression – Not currently publicly funded for this regimen and intent |
| IBRU | Ibrutinib 420 - 560 mg PO daily – Not currently publicly funded for this regimen and intent |
| OBIN(MNT) | oBINutuzumab 1000 mg IV day 1 – not currently publicly funded for this regimen and intent; Q8 weeks (until disease progression or for up to 2 years) |

Hairy Cell Leukemia

| Regimen Code | Regimen Abstract |
|--------------|--|
| CLAD | <p>Cladribine 0.12-0.14 mg/kg IV days 1-5</p> <p><i>Alternative schedules:</i> Cladribine 0.09 - 0.1 mg/kg CIV for 5-7 days Cladribine 0.14mg/kg IV weekly for 6 weeks</p> |
| CLAD+RITU | <p>Cladribine 0.12-0.14 mg/kg IV days 1-5; riTUXimab 375 mg/m² IV weekly for 4 - 8 weeks. Rituximab can be given concurrently or following Cladribine</p> <p><i>Alternative schedule:</i> Cladribine 0.09 - 0.1 mg/kg CIV For 5-7 days riTUXimab 375 mg/m² IV weekly for 4 - 8 weeks. Rituximab can be given concurrently or following Cladribine</p> |
| IFNA(SC) | Interferon 2 MU/m ² SC 3 times/week |

Last Updated: November 2017